Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options

The piece analyzes a trade idea to sell the January 2028 $8 put on Corvus Pharmaceuticals (CRVS), noting the put premium implies a 10.2% annualized return but only results in owning shares if CRVS falls ~62.9% and the contract is exercised—yielding a net cost basis of $6.40 per share after the $1.60 premium. It highlights the stock's current price of $21.47 and a very high trailing-12-month volatility of 122%, framing the risk/reward for potential put sellers rather than company fundamentals.

Analysis

Market structure: The immediate winners are option premium sellers and brokers collecting fees; buyers of protection (hedgers/speculators) pay for convexity. The $8 Jan‑2028 put on CRVS yields 10.2% annualized versus a spot of $21.47 and implied/realized volatility ~122%, which signals the market assigns a low but non‑negligible tail probability to a >62.9% collapse to $8 by 2028. Cross‑asset: a binary negative biotech outcome would lift Treasury bids, widen high‑yield spreads and spike equity implied vol across small‑cap biotech indices within days–weeks.

Risk assessment: Tail risks are classic biotech binaries — negative trial/FDA news, unexpected cash burn leading to a dilutive secondary, or sponsor insolvency; any one can trigger 70–90% drawdowns. Short horizon (days–weeks) risk is IV repricing on headlines; medium (3–12 months) is runway and financing risk (likely secondary within 6–12 months if cash low); long (1–3 years) outcome is product approval/failure or repeated dilution. Hidden deps include liquidity for assignment, borrow/margin dynamics, and correlation with broader small‑cap fund flows that can cascade.

Trade implications: If willing to own CRVS at a deep discount, consider a small, cash‑secured put sell (Jan‑2028 $8) sized 0.5–1.0% of portfolio — be prepared to own at $6.40 net. If bearish, buy downside protection (9–12m puts) or short CRVS size 0.5% with tight risk control; for sector exposure, long large‑cap biotech ETF (IBB) vs short a microcap biotech basket including CRVS for 3–6 months to capture flight‑to‑quality. Options strategies: prefer defined‑risk structures (put spreads, calendar spreads) over naked short puts given IV and tail risk.

Contrarian angles: The consensus underestimates assignment risk and potential dilution; 10.2% p.a. looks superficial relative to 122% vol because the strike is deep OTM — premium inadequate for a buy‑and‑hold short‑tail exposure. Historical parallels (small‑cap biotech flop cycles) show one negative catalyst can wipe >80% value; the trade is mispriced only if you truly want to own at the $6.40 implied breakeven. Unintended consequence: widespread put selling into illiquid tape can create sudden forced selling/assignment and then a painful capital call for sellers.

Key Decisions for Investors

• Establish a cash‑secured short position: sell CRVS Jan‑2028 $8 puts sized to 0.5–1.0% of portfolio only if you are willing to own shares at $6.40 net; set a hard buy‑to‑close if CRVS trades below $12 for two consecutive sessions or implied vol >200% to limit assignment risk.
• If bearish or event‑driven, buy 9–12 month protective puts (e.g., Sep‑Dec 2026 $15 strikes) sized to 0.5% portfolio as a tail hedge; target profit / close if CRVS > $30 or after a positive pivotal readout (take profits at 50–70% of option premium).
• Implement a 3–6 month pair trade: go long 2% IBB (large‑cap biotech) and short equal dollar microcap biotech basket including CRVS (reweight if CRVS weight >20% of the short leg); close if relative outperformance exceeds 8% or after the next quarterly results window.
• Do not increase net exposure before confirming two fundamentals: (1) cash runway disclosed in next 60 days (enough to reach next catalyst without >30% dilution risk) and (2) absence of pivotal readout in the following 6 months; use these data points to move from tactical option plays to equity ownership.